Literature DB >> 9038722

Binding of human and rat CD59 to the terminal complement complexes.

T Lehto1, B P Morgan, S Meri.   

Abstract

CD59-antigen (protectin) is a widely distributed glycolipid-anchored inhibitor of complement lysis. CD59 interacts with complement components C8 and C9 during assembly of the membrane attack complex (MAC). To evaluate species specificity of these interactions we have in the present study examined cross-species binding of isolated human and rat CD59 to the terminal complement components C8 and C9. By using primarily soluble CD59 isolated from urine (CD59U) potentially non-specific binding interactions of the phospholipid portion of the membrane forms of CD59 could be avoided. Sucrose density gradient ultracentrifugation analysis showed that human CD59U bound to both human and rat C8 in the SC5b-8 complexes. Similar binding occurred when rat CD59U was used. The degree of binding did not significantly differ between the heterologous and homologous CD59-C8 combinations. C9 from both species inhibited the binding of CD59 to soluble SC5b-8. In ligand blotting analysis human and rat CD59U bound to human and rat C8 alpha gamma-subunit and C9. Binding of human and rat CD59U was stronger to human than rat C9. In plate binding assays the erythrocyte form of CD59 (CD59E) bound to both human and rat C8. Binding of CD59E to heterologous C9 was considerably weaker than to homologous C9. Our results imply that the reciprocal binding sites between C8 and CD59 and to a lesser degree between CD59 and C9 are conserved between human and rat. Interactions of CD59 with the terminal C components are thus species selective but not 'homologously restricted'.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038722      PMCID: PMC1456727          DOI: 10.1046/j.1365-2567.1997.00120.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.

Authors:  N K Rushmere; R A Harrison; C W van den Berg; B P Morgan
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

2.  Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).

Authors:  R V White; K M Kaufman; C S Letson; P L Platteborze; J M Sodetz
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

3.  Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell-surface protein domain related to snake venom neurotoxins.

Authors:  B Kieffer; P C Driscoll; I D Campbell; A C Willis; P A van der Merwe; S J Davis
Journal:  Biochemistry       Date:  1994-04-19       Impact factor: 3.162

4.  Regulation of CD59 expression on the human endothelial cell line EA.hy 926.

Authors:  S Meri; P Mattila; R Renkonen
Journal:  Eur J Immunol       Date:  1993-10       Impact factor: 5.532

5.  Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.

Authors:  T Lehto; S Meri
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

6.  Sequence-specific 1H-NMR assignments and folding topology of human CD59.

Authors:  C M Fletcher; R A Harrison; P J Lachmann; D Neuhaus
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

7.  Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.

Authors:  H Ninomiya; B H Stewart; S A Rollins; J Zhao; A L Bothwell; P J Sims
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

8.  Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection.

Authors:  H Takizawa; K Takahashi; T Murakami; N Okada; H Okada
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

9.  Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted.

Authors:  C W van den Berg; B P Morgan
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

10.  Primate terminal complement inhibitor homologues of human CD59.

Authors:  W L Fodor; S A Rollins; S Bianco-Caron; W V Burton; E R Guilmette; R P Rother; G B Zavoico; S P Squinto
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

View more
  4 in total

1.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

2.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

3.  Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.

Authors:  Jijun Xu; Lingjun Zhang; Mian Xie; Yan Li; Ping Huang; Thomas L Saunders; David A Fox; Richard Rosenquist; Feng Lin
Journal:  J Immunol       Date:  2018-04-25       Impact factor: 5.422

4.  Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.

Authors:  Pamela Ghosh; Anand Vaidya; Rupam Sahoo; Allison Goldfine; Neil Herring; Lynn Bry; Michael Chorev; Jose A Halperin
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.